News

Repeated injections with preoperative povidone-iodine application was associated with reduced meibomian gland loss, increased tear volume, and reduced signs of inflammation.

Hospital lengths of stay, costs, and readmissions were all reduced after implementing an antimicrobial stewardship program.

After addressing a 2021 CRL, Verrica Pharmaceuticals vies for the agent to become the first drug approved to treat the common skin infection.

The SPRINT MIND trial is providing new evidence related to the effects of intensive blood pressure lowering on cognitive impairment and risk of dementia according to baseline diastolic blood pressure

New research connected dupilumab levels to OSD in atopic dermatitis patients, indicating a contribution to the development of the condition.

A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.

Results from the ACTIVE-AF trial indicate participation in an exercise-based intervention reduced arrhythmia recurrence and improved symptom severity among patients with AF.

Men in the highest quartile of PDE-5i exposure had the lowest incidence of MACE and overall mortality compared to the lowest exposure quartile.

Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

A new study from clinicians in the VA Boston Healthcare System provides an overview of the impact the COVID-19 pandemic has had on racial disparities in wait times for new cardiology and orthopedic specialist consultations.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Using data from the STEP 5 trial, investigators provide new insight into the effects of semaglutide 2.4 mg on hunger and cravings among people with overweight and obesity, with results also shedding light on how these effects correlate to weight loss in the trial.

New research on updadacitinib’s use for atopic dermatitis patients suggests the drug may be effective for hand eczema.

The safety and efficacy of 4 adalimumab biosimilars was compared in a real-life setting in adult patients with IBD switching from the originator for a non-medical reason.

Dr. Neomi Shah explains why improving access to behavioral care for insomnia needs to be prioritized.

Eyes treated with pegcetacoplan showed a significantly slower GA lesion progression rate compared with sham, and slower growth rate toward the fovea.

In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

The study evaluated how intranasal mometasone furoate affected sleep-disordered breathing symptoms and patient quality of life by comparing its efficacy to intranasal saline in the pediatric patients.

6-year results from the LiGHT trial suggest SLT is a safe treatment for eyes with open-angle glaucoma and ocular hypertension, providing drop-free IOP control.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.

An analysis of data from the STS Adult Cardiac Surgery Database provides an updated overview of the risks of mortality, morbidity, and conversion-to-replacement among patients undergoing mitral valve repair for primary mitral regurgitation.

A phase 4, post-marketing surveillance study in Korea provides insight into the safety and efficacy of SB2, an infliximab biosimilar, across a wide range of immune-mediated inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.

A discussion with Henry Lim, MD, during an interview segment in which he described photoprotection measures for various skin phenotypes and his outlook on future research.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.